[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2013/184757,2013,A1Locationinpatent:Page/Pagecolumn125
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2013/184757,2013,A1Locationinpatent:Page/Pagecolumn125;126
[2]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2016/55916,2016,A1Locationinpatent:Page/Pagecolumn5
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2013/184757,2013,A1
[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/81463,2015,A1
[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/85482,2015,A1
[4]Lelais,Gérald;Epple,Robert;Marsilje,ThomasH.;Long,YunO.;McNeill,Matthew;Chen,Bei;Lu,Wenshuo;Anumolu,Jaganmohan;Badiger,Sangamesh;Bursulaya,Badry;DiDonato,Michael;Fong,Rina;Juarez,Jose;Li,Jie;Manuia,Mari;Mason,DanielE.;Gordon,Perry;Groessl,Todd;Johnson,Kevin;Jia,Yong;Kasibhatla,Shailaja;Li,Chun;Isbell,John;Spraggon,Glen;Bender,Steven;Michellys,Pierre-Yves[JournalofMedicinalChemistry,2016,vol.59,#14,p.6671-6689]
[1]Patent:WO2013/184757,2013,A1
[2]Patent:WO2015/81463,2015,A1
[3]Patent:WO2015/85482,2015,A1
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2013/184757,2013,A1
[2]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/81463,2015,A1
[3]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2015/85482,2015,A1
[4]Lelais,Gérald;Epple,Robert;Marsilje,ThomasH.;Long,YunO.;McNeill,Matthew;Chen,Bei;Lu,Wenshuo;Anumolu,Jaganmohan;Badiger,Sangamesh;Bursulaya,Badry;DiDonato,Michael;Fong,Rina;Juarez,Jose;Li,Jie;Manuia,Mari;Mason,DanielE.;Gordon,Perry;Groessl,Todd;Johnson,Kevin;Jia,Yong;Kasibhatla,Shailaja;Li,Chun;Isbell,John;Spraggon,Glen;Bender,Steven;Michellys,Pierre-Yves[JournalofMedicinalChemistry,2016,vol.59,#14,p.6671-6689]
Title: Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.
Journal: Cancer science 20160901
Title: Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Journal: Journal of medicinal chemistry 20160728
Title: Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Journal: Journal of medicinal chemistry 20160728
Title: EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
Journal: Cancer research 20160315
Title: Lelais G, et al. Discovery of (R,E)-N-(7-Chloro-1-(1--(dimethylamino)but-2-enoylazepan-3-yl)-1H-benzo[dimidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T79
Title: Jia Y, et al. EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Res. 2016 Mar 15;76(6):1591-602
